A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adults

A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adults - A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009074

Enrollment

110

Registered

2012-10-10

Start date

2012-10-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (ERL) -Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria and 12 months or more disease duration (LN) -Diagnosis of SLE according to current ACR criteria and diagnosis of Class III or IV lupus nephritis based on International Society of Nephrology/Renal Pathology Society -1+ or more Proteinuria with qualitative urinalysis -Protein uria with a urinary protein/creatinine ratio of 0.5 or higher (Healthy adults) -Healthy Japanese

Exclusion criteria

Exclusion criteria: (ERL/LN) -Unstable neuropsychiatric SLE at the time of sampling. -Evidence of significant uncontrolled concomitant diseases (e.g., cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders) at the time of sampling. -Conditions other than SLE that could require treatment with corticosteroids (e.g., asthma) at the time of within 12 months prior to sampling. -History of cancer within 5 years prior to sampling. -History of congenital immunodeficiency. -Signs or symptoms of infection within 31 days prior to sampling (Healthy adults) -Evidence of concomitant diseases (e.g., cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders) at the time of sampling. -History of cancer within 5 years prior to sampling. -Any clinically abnormal conditions at the time of sampling. -Signs or symptoms of infection within 31 days prior to sampling.

Design outcomes

Primary

Measure	Time frame
IRGs expression levels in Japanese SLE patients	—

Countries

Japan

Contacts

Public ContactMasato Okada

St.Luke's International Hospital Division of Allergy & Rheumatology (SLE, rheumatoid arthritis, pediatric rheumatology)

Outcome results